Hsp90 Inhibitor-Evodiamine Conjugates: In Vitro and In Vivo Antitumor Activity Data

A dataset from figshare details a series of rationally designed heat shock protein 90 (Hsp90) inhibitor-evodiamine conjugates for colon cancer therapy. The data includes specific in vitro antiproliferative activity (IC50 = 7.7 nM) and in vivo tumor growth inhibition results (TGI up to 72.9%) for a lead compound. It was authored by Yuhang Sun and last updated on 2026-05-28.

Use Cases

• Training predictive models for antitumor efficacy based on conjugate chemical structures.
• Benchmarking new Hsp90 inhibitor designs against the reported IC50 values.
• Analyzing structure-activity relationships for evodiamine derivatives.
• Comparing in vitro and in vivo performance metrics for drug candidate evaluation.

Strengths

• Includes specific, quantitative efficacy metrics (e.g., IC50 = 7.7 nM, TGI = 72.9%).
• Data describes results from both in vitro and in vivo experimental models.
• Dataset is openly shared under the CC-BY-NC-4.0 license.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is very small (2.6 KB), indicating limited scope.

Provenance

Source

figshare

Collection Method

Likely contains experimental results from the synthesis and testing of novel chemical conjugates.

Freshness

Last updated 2026-05-28 19:45:24; freshness should be verified.